FDA Brief

Warning letters Food

FDA warning letter to

Rosebud's Ranch and Garden, LLC

MediumIssued Oct 18, 2022Posted Nov 22, 2022Division of Human and Animal Food Operations East V

FDA warned Rosebud's Ranch and Garden that disease-treatment claims on its websites make several teas, syrups, seasonings, and sauces unapproved and misbranded drugs.

What happened

FDA reviewed the company's website and Facebook page in June and August 2022. It found claims that products such as teas, elderberry syrup kit, lemonade, seasonings, fruit butter, and sriracha treat, prevent, or cure diseases including colds, flu, pain, high blood sugar, and cancer. FDA says these claims make the products drugs, but they are not approved and lack adequate directions.

What FDA found

  1. Website and Facebook claims that the products cure, mitigate, treat, or prevent disease make them drugs under the law.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for the claimed uses, and FDA has not approved them.

    FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products lack adequate directions for use, so they are misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. For seven products, the claimed uses are for diseases that a layperson cannot safely diagnose or treat without a licensed practitioner, so adequate directions cannot be written.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]
  5. Selling or shipping these misbranded drugs in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with related documents. If corrections cannot be completed in that time, the company must explain the delay and say when it will finish.

Who should pay attention

  • food and beverage brands that make health claims online
  • online retailers selling teas, syrups, and sauces with disease claims
  • marketing teams posting product health claims on social media

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk